Low-Dose Radiation Therapy to See if It Helps Alzheimer's and Inflammatory Dementias

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study investigates the safety and tolerability of a low-dose whole brain radiotherapy regimen for Alzheimer's disease and related dementias with inflammatory components. The induction course is 0.3 Gy × 10 fractions (3.0 Gy total), followed by 12 months of monthly maintenance doses of 0.3 Gy × 10 fractions (3.0 Gy total). Participants will be adults aged 50 years or older with confirmed inflammatory or inflammatory-featured neurodegenerative dementia, and a MoCA score between 10 and 25 at baseline. The trial is conducted at a single center (Renaissance Institute of Precision Oncology & Radiosurgery) with a defined adult-onset dementia population and requires caregiver support for attendance. Primary aims focus on safety and tolerability, with exploratory signals related to cognitive trajectory and inflammatory biomarkers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥50 years at time of enrollment
2. Externally confirmed diagnosis by a neurologist or geriatric psychiatrist (at Renaissance Institute, collaborating neurologist Dr. Sherif Makar, MD of Charis Neurology is available for diagnostic consultation) of one of the following: a. Alzheimer's disease (per NIA-AA 2011 or 2018 criteria) b. Frontotemporal dementia with documented inflammatory features c. Dementia with Lewy bodies with elevated inflammatory CSF markers d. Other neurodegenerative dementia with confirmed inflammatory component (elevated CSF IL-6, IL-1β, or TNF-α; or neuroimaging evidence of neuroinflammation)
3. MoCA score 10-25 at baseline screening (moderate-to-mild cognitive impairment range)
4. Karnofsky Performance Status (KPS) ≥60 or ECOG Performance Status ≤2
5. Medically stable and capable of receiving radiation therapy as assessed by the treating radiation oncologist
6. Reliable caregiver or informant able to accompany the patient to ≥80% of scheduled visits
7. Written informed consent from patient (if decision-making capacity is preserved) and/or legally authorized representative (LAR); caregiver co-consent required
8. Life expectancy ≥18 months in the opinion of the treating physician
9. Ability and willingness to comply with monthly clinic visits for the 12-month maintenance period

   \--------------------------------------------------------------------------------------

Exclusion Criteria:

1. Prior whole brain or partial brain radiotherapy of any dose at any time
2. Active systemic malignancy requiring concurrent oncologic treatment
3. Implanted device contraindicated with radiation therapy (pacemaker, cochlear implant, deep brain stimulator, or equivalent)
4. Brain MRI demonstrating any of the following: (a) more than 4 cerebral microhemorrhages on susceptibility-weighted imaging (SWI) or gradient echo (GRE) sequences; (b) more than 1 area of superficial cortical siderosis; (c) severe white matter disease (Fazekas grade 3); or (d) any macrohemorrhage or hemosiderin-stained lesion \>10 mm. These thresholds are adapted from established AD trial imaging exclusion criteria to minimize enrollment of patients with advanced cerebrovascular disease or pre-existing hemorrhagic risk factors.
5. Known active cerebral amyloid angiopathy-related inflammation (CAA-ri) or amyloid-related beta-angiitis (ABRA), whether confirmed by biopsy, CSF analysis, or neuroimaging features consistent with active leptomeningeal or parenchymal amyloid-related inflammation
6. Active autoimmune encephalitis in acute phase (patients in stable chronic phase are eligible)
7. Uncontrolled systemic infection or active sepsis at enrollment
8. Severe psychiatric comorbidity (active psychosis, active suicidal ideation) impairing protocol compliance or safety assessment
9. Concurrent enrollment in another interventional trial targeting cognitive decline or neuroinflammation
10. Pregnancy or lactation; women of childbearing potential must use adequate contraception
11. Inability to lie flat and still for radiation delivery (approximately 10-15 minutes per session)
12. MoCA \<10 at baseline screening (severe dementia; insufficient cognitive range for endpoint assessment)

Where it's running

• Renaissance Institute of Precision Oncology & Radiosurgery
  Winter Park, Florida, United States Recruiting

Study contacts

• Principal investigator: Evan Thomas, MD, PhD — Renaissance Institute of Precision Oncology and Radiosurgery
• Study coordinator: Julia Pierson, BS
• Email: jpierson@therenaissanceinstitute.org
• Phone: 321-972-1102

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

• Brain stimulation plus methylphenidate for apathy in Alzheimer's

  This trial will test whether combining short sessions of noninvasive brain stimulation (intermittent theta burst) with methylphenidate can reduce apathy in people with Alzheimer's disease or mixed Alzheimer's/vascular dementia.

  Recruiting Phase 2 Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT07279740

• Aging Brain Health Initiative in Fujian

  This observational study will follow about 3,000 older adults in Fujian to see how Alzheimer's-related changes develop and to test new digital tests, biomarkers, and imaging tools for early diagnosis.

  Recruiting at 4 sites Fujian Medical University Union Hospital · Fushun, Fujian and 3 other locations · NCT07891429

• Restoring Cervical Lymphatic Drainage in Alzheimer’s Disease

  A small study tests whether a minimally invasive surgery to improve cervical lymphatic drainage can affect biomarkers, brain imaging, and cognition in people with Alzheimer's who can’t access other disease-modifying therapies.

  Recruiting University of Siena · Siena, Tuscany · NCT07854327

• Risk-score predictor for dementia in older adults with depression

  This study tests whether a point-based risk score from electronic medical records can accurately predict which older adults with depression will develop dementia.

  Recruiting Second Affiliated Hospital of Nanchang University · Nanchang, Jiangxi · NCT07676851

• Brain wave‑guided noninvasive brain stimulation to help working memory in dementia

  This study tests whether synchronizing brain waves with EEG‑guided transcranial magnetic stimulation can improve working memory in people with dementia or Alzheimer's disease.

  Recruiting McMaster University · Hamilton, Ontario · NCT07673770

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.